Introduction
Molecular mechanisms underlying atherosclerotic plaque instability are incompletely understood. The central event of the haemostatic process is the generation of thrombin through the tissue factor (TF) pathway. Tissue factor after interaction with plasma factor VII at the site of vessel injury activates factor X and IX, leading to thrombin generation. Within atherosclerotic plaques, TF is expressed by vascular smooth muscle cells (VSMCs), monocytes, macrophages and endothelial cells. 1 Increased expression of TF has been found in atherosclerotic plaques from patients with unstable angina and myocardial infarction. 2 It has been also demonstrated in a rabbit model that atherosclerotic plaque rupture is associated with increased TF production from circulating monocytes. 3 TF overexpression in rat arterial neointima may influence lesion development through coagulationdependent and -independent mechanisms and provoke progression of advanced atherosclerosis through its important role in neointimal formation. 4 Tissue factor is considered to be the principal molecule linking plaque inflammation with arterial thromboembolism. 5, 6 Activating protease activated receptors (PARs) on vascular cells TF may contribute to other, non-haemostatic, biological processes. 7, 8 The main inhibitor of coagulation is tissue factor pathway inhibitor (TFPI) which is believed to play a crucial role in the regulation of the function of vascular wall cells. TFPI is able to modulate cell proliferation. 1 TFPI is mainly associated with the surface of endothelium and may be a marker of endothelial cell dysfunction. 1 Recent reports suggest that TFPI may attenuate thrombosis and prevent restenosis. The process of neovascularisation is thought to be responsible for atherosclerotic plaque destabilization and acceleration of plaque growth through episodes of intraplaque microhemorrhages. Vascular endothelial growth factor-A (VEGF-A) is crucially involved in the process of angiogenesis [9] [10] [11] [12] [13] and, therefore, its concentration in the 'active', destabilized carotid plaque is speculated to be closely connected with TF and TFPI plaque levels. It has been reported that immature vessels formed during neovascularisation inside atherosclerotic plaque may be the most important source of the inflammatory focus. 14 In our previous study, we have demonstrated that the haemostatic profile of a symptomatic carotid plaque differs from that of an asymptomatic plaque. 15 Thrombin generation was significantly higher in symptomatic carotid plaques (TAT). 15 The haemostatic composition of carotid plaque of patients with coexisting diabetes was also different (increased concentration of thrombin-antithrombin complexes, tissue plasminogen activator and D-dimers). 15 It has been also demonstrated that the carotid plaque of diabetic patients differs with respect to content of selected markers of endothelial activity (thrombomodulin, endothelin, E-selectin, P-selectin). 16 In this project we investigate the concentrations of tissue factor (TF), tissue factor pathway inhibitor (TFPI) and vascular endothelial growth factor A (VEGF-A) in frozen samples of carotid atherosclerotic plaques. The aim of the present study was to determine the correlation between levels of tested factors (TF, TFPI, VEGF-A) in carotid plaques and blood plasma.
Material and Methods
Frozen carotid plaques of 38 patients undergoing carotid endarterectomy in the Department of Surgery were used to perform the study. Complete medical history of all patients was available, and the following risk factors and coexisting diseases were recorded: sex, age, body weight, hyperlipidemia (total cholesterol, LDL, HDL, triglyceride), smoking status (1, never smoked; 2, former smokers-quit O1 year; 3, current smoker), peripheral arterial occlusive disease (ABPI! 0.9), hypertension (under hypotensive therapy or blood pressure R160/95 mmHg), coronary artery disease (angina pectoris, myocardial infarction, coronary artery bypass grafting procedure or PTCA) and diabetes (patients on diet, oral hypoglycemic agents, insulin or with fasting glucose levels O126 mg/dl). Patients were defined as symptomatic if symptoms occurred less then 6 months before enrollment. In all patients, the neck arteries were investigated by color duplex ultrasound (7.5-MHz linear transducer, ATL HDI 3500). Four patients in which the carotid arteries were difficult to visualise by duplex underwent angiography. The carotid stenosis was evaluated using widely accepted diagnostic criteria for the classification of carotid artery disease using mainly velocity measurements. 17 A peak systolic velocity (PSV) of R125 cm/s was the threshold for the diagnosis of a stenosis graded R50%. Higher-degree stenoses were graded in categories of 5%, taking into account the peak systolic velocity (PSV) and end diastolic velocity in the jet of the stenosis, the peak systolic velocity in the most distal poststenotic ICA, spectral broadening and ICA/CCA PSV ratio. When the ICA PSV was R230 cm/s a stenosis of R70% was diagnosed.
Sample preparation
Carotid plaques removed during endarterectomy were washed carefully in saline and stored dry in the freezer (at K20 8C). Venous blood samples (15 ml) were collected in the fasting state before the operation (8 a.m.). The blood was collected into a plastic centrifugation-tube containing 3.8% natrium citrate solution (1:10 proportion). Blood samples were centrifuged immediately after sampling in order to obtain platelet-free plasma (3000/min; 15 min). Platelet-free plasma samples were stored at K20 8C. The concentration of tissue factor, TFPI and VEGF-A in homogenates was tested in the laboratory of Department of Pathophysiology using enzyme immunoassay (ELISA). The concentration of TF, TFPI and VEGF-A in carotid plaques was calculated per milligram protein of homogenates. The measurement of the concentration of tested factors in plasma enabled the evaluation of correlation between concentration of individual factors in carotid plaques and blood plasma. Tests used in the present study: asymptomatic carotid stenosis and the concentration of tested factors in carotid plaques was examined using the Mann-Whitney test. Student's t-test was used for comparison of two groups of values with normal distribution. Correlation was calculated according to Pearson. The Chi-squared test with Yates modification was used for comparison of differences in risk factors and coexisting disease distribution. The criterion for statistical significance was p!0.05.
Results

Patient demographics
Thirty-eight patients (26 men, 12 women, median age 67) were enrolled into the study. Twenty subjects had symptomatic carotid stenosis and the other 18 patients had no characteristic cerebral ischemic symptoms. Most individuals were current and former smokers (nZ33, 86.8%). Among 33 smokers, 18 (47.4%) were current smokers and 15 (39.5%) stopped smoking more than 1 year ago. Among all the patients enrolled in the study 25 (65.8%) had hypertension and 7 (18.4%) diabetes. Concomitant peripheral arterial occlusive disease (PAOD) was found in 26 patients (68.4%). Eighteen of these patients reported intermittent claudication and eight individuals had no symptoms of PAOD. Most of enrolled subjects were overweight (nZ22) or obese (nZ11) ( Table 1 ). The median carotid stenosis severity was 75% overall (range 50-95%), 80% for symptomatic patients (range, 50-95%) and 70% for asymptomatic patients (range, 50-95%). None of studied patients were on statins therapy prior to surgery. All of enrolled patients were on the aspirin therapy (75 mg daily). There were no statistically significant differences with respect to sex, age, risk factors distribution and degree of stenosis between symptomatic and asymptomatic patients.
There were increased mean concentrations of TF and VEGF-A in carotid plaque homogenates in comparison to plasma level of these factors. The concentration of TF in carotid plaque homogenates was almost 60 fold higher than in blood plasma. The plasma TF level in study patients was within the normal range and the mean plasma concentration of VEGF was higher than normal ( Table 2) . A low concentrations of TFPI in carotid plaques homogenates was observed, 80 fold below the mean plasma levels of TFPI (Table 2 ). There were no statistically significant differences between concentration of TF, TFPI and VEGF-A in carotid plaques of symptomatic and asymptomatic patients ( Table 3) .
The influence of concomitant risk factors and diseases on the level of TF, TFPI and VEGF-A in the carotid plaque was evaluated. We demonstrated increased concentrations of TF and VEGF-A in the atheroma of diabetic patients (pZ0.002, pZ0.005, respectively). There was also a trend toward increased concentration of TFPI (pZ0.07) in carotid plaques of diabetic patients but the difference did not reach statistical significance. The small sample size likely influenced the results (subgroup of diabetic patients nZ7) (Table 4 ). There were no differences between plasma concentration of TF, TFPI and VEGF-A in diabetic and non-diabetic patients. The concentration of VEGF-A was elevated in the carotid plaques of older patients (age R65, pZ0.02) ( Table 5) . Statistically significant increased levels of TFPI in the carotid plaque of non-smokers were demonstrated (pZ0.03) ( Table 5 ). There was no difference in the plaque concentration of TF and VEGF-A in carotid plaque of smokers and non-smokers. The composition of preocclusive carotid plaques (R90% of stenosis) did not differ from those with less advanced stenosis ( Table 5) . There was no difference in the plaque concentration of TF, TFPI and VEGF-A in hypertensive and normotensive patients. Reference data/normal plasma levels: TF (28-255 pg/ml), TFPI (75-120 ng/ml), VEGF-A (75-140 pg/ml).
A highly positive correlation between concentration of TF, TFPI and VEGF-A in the blood plasma and the carotid plaque homogenates was found. The correlation coefficients of Person (R) and p-values were, respectively: TF (0.86/!0.0001); TFPI (0.91/!0.0001); VEGF-A (0.80/0.001). A positive correlation between the plaque concentration of VEGF-A and TF, TFPI was also observed (Table 6 ).
Discussion
The fibrous cap is the structure that separates the blood stream from the necrotic core of the carotid plaque. 18 Fibrous cap rupture is believed to be the main mechanism of carotid plaque destabilization and embolization. It has been demonstrated that fibrous cap rupture is more common in plaques with increased inflammatory cells (macrophages and Tcells). 19 Plaque rupture exposes the necrotic core to the blood stream and the TF pathway is activated. In the healthy vessel wall TF is present only in the adventitia. In atherosclerotic arteries TF is also present in the intima. It has been demonstrated that there is a significant positive association between TF expression and intraplaque inflammatory cells content. 20 In our previous study we demonstrated that thrombinogenesis is increased in symptomatic carotid plaques 15 and we expected to find increased concentration of TF in these plaques but surprisingly we have found no difference between the concentration of TF in symptomatic and asymptomatic plaques. Jander et al. using immunocytochemistry found a higher expression of TF in symptomatic carotid plaques. 20 Furthermore, they demonstrated a highly significant association of TF expression with the occurrence of cerebral microembolism. 20 In our present study the mean concentration of TF and TFPI measured with the ELISA technique in symptomatic and asymptomatic plaque was similar. The methodology differences between this study and that of Jander and colleagues may explain the disparate findings. There are also reports demonstrating higher TF levels in atheroma from patients with unstable angina compared with stable angina. 21 Additional studies using TF are mandatory to clarify its role in carotid plaque 'activation'. Probably the expression of TF (expressed by macrophage-derived foam cells 22 ) is higher only in some areas of symptomatic plaques were the number of inflammatory cells is greatest. 20 In healthy subjects TF antigen is present in the plasma at a mean level of 149-172 pg/ml. 23, 24 Some recent studies have shown that the levels of bloodborn TF are increased in atherosclerosis. [25] [26] [27] Our study has demonstrated that mean TF plasma concentration in patients with advanced carotid atherosclerosis is within the normal range (mean 127G83 pg/ml) but the mean TF concentration in carotid plaque homogenates was almost 60 fold higher than in blood plasma (mean 7478G2354 pg/ml) ( Table 2) .
Caplice et al. have demonstrated that TFPI is present within human atherosclerotic plaques and may modulate plaque thrombogenicity by attenuating TF activity. 28 In Caplice study TFPI was undetectable in 30% of the plaque samples, suggesting that there may be plaques relatively deficient in TFPI. 28 In the present study, we found TFPI in all tested carotid plaques. We did not find statistically significant differences in TFPI concentrations between symptomatic and asymptomatic plaques. We did demonstrate increased level of TFPI in the carotid plaques of non-smokers. Considering the potential active role of TFPI in the prevention of thrombotic complications 29, 30 we assume that attenuated function of TFPI in smokers suffering from advanced arteriosclerosis will predispose them to a higher risk of thromboembolic complications. We demonstrated in our earlier study that the most marked changes in the carotid plaque haemostatic composition was in diabetic patients (increased TAT, t-PA and D-dimers level). 15 In the present study, we show that diabetic patients have increased level of TF and VEGF-A in their carotid atheroma (Table 4) . There was also a trend towards increased concentration of TFPI in the carotid plaques of diabetic patients (2.3 vs. 1.6 ng/mg p; pZ0.07) but the difference did not reach statistical significance. Possibly the small sample size influenced these results. The increased expression of TF in type 2 diabetes mellitus correlated with components of the metabolic syndrome has previously been reported. 31 The other important trigger mechanism of destabilization and acceleration of an atherosclerotic plaque growth is believed to be intraplaque microhemorrhage. Intraplaque neovascularization and hemorrhage may facilitate plaque progression. VEGF-A acts on endothelial cells (stimulating endothelial proliferation and migration) and monocytes which participate in the angiogenic process. 13, 32 Small, vulnerable vessels are formed during the neovascularization process inside advanced atheroma. Such vessels are particularly susceptible to rupture. During the intraplaque microhemorrhage the coagulation process is activated. VEGF-A and its receptors are crucially involved in process of angiogenesis 9-13 and we believed that VEGF-A could be a good marker of neovascularisation activity. Therefore, we expected to find increased concentration of VEGF-A inside symptomatic carotid plaques. In our present study there were no differences in VEGF-A concentration between symptomatic and asymptomatic carotid plaque but we did find statistically significant increased VEGF-A level in carotid plaques of diabetic patients (Tables 3  and 4 ). This is an interesting finding in light of earlier reports that specific and strong VEGF-A-induced chemotactic response of monocytes are attenuated in diabetic patients. 33 It has been demonstrated by Ferrara et al. that diabetic retinopathy is associated with high intraocular levels of VEGF-A. 34 It has been also reported that TF may play an additional non haemostatic role in blood vessel development. 35 The carotid plaques of diabetic patients in our study group were characterized by increased concentration of TF and VEGF-A (Table 4) . These findings indicate not only increased haemostatic activity but also greater angiogenesis in these plaques. We assume that neovascularisation, consecutive intraplaque microhemorrhages and TF pathway activation could be the crucial processes determining the activity of diabetic patients' carotid plaques. An association of angiogenic mediators with microvessels and with the severity of atherosclerosis has recently been reported. 36 Our finding suggests that neovascularisation could be a crucial mechanism responsible for more aggressive progress of atherosclerosis in diabetic patients.
It has been reported that the normal median plasma level of VEGF-A in healthy individuals is 98 pg/ml (25th and 75th percentiles, 75 and 137 pg/ml). 33 Our study patients with advanced carotid atherosclerosis had increased plasma level of VEGF-A (mean 504 pg/ml)( Table 2) .
On the basis of our present and former studies 15 we assume that thrombin (as TAT complexes) but not TF could be a good marker of 'active' carotid plaque. We have found increased concentration of thrombinantithrombin complexes (TAT) in symptomatic carotid plaques but the concentration of TF in these plaques was not elevated. That could means that thrombin activation takes place through TF independent pathways, such as platelet-located activation of thrombin by factor XI. 37 The available data provides evidence that thrombin signaling in vascular development cannot be explained by a model based only on the classic extrinsic and intrinsic coagulation pathways. 38 Thrombin is one of the most potent stimuli for nonhypoxic VEGF expression 39 and also upregulates VEGF receptors in endothelial cells 40 which may explain the effects of thrombin on angiogenesis and vascular development. 41 VEGF in turn accelerates thrombin generation, suggesting that these two factors act as part of a positive feedback loop to accelerate the angiogenic process. 42 We must underline the limitations of the present study. The study would benefit from control samples of the carotid wall (potentially free of athermanous changes). We used ELISA tests for quantitative determination of concentration of TF, TFPI and VEGF-A in carotid plaques homogenates. It is possible that the expression of the tested factors is higher only in some areas of carotid plaque. Using different techniques for the calculation of expression of these factors in the carotid plaques (ELISA, immunochemistry or Western blotting) would further clarify this issue.
Conclusions
Symptomatic and asymptomatic plaques do not differ with respect to TF, TFPI and VEGF-A mean concentration. The concentration of VEGF-A in carotid plaques correlate positively with TF and TFPI levels. Among risk factors of atherosclerosis diabetes exerts the most marked influence on the concentration of TF and VEGF-A in carotid plaques homogenates. 
